Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Int J Gynecol Cancer. 2010 Oct;20(7):1290–1298. doi: 10.1111/IGC.0b013e3181ee1c01

Table 2.

Current GCIG phase III and randomized phase II clinical trials for women with ovarian cancer (included recently closed trials, trials open to accrual, and trials in final design)

Disease trajectory Name of study Lead and collaborating groups Clinical question Outcome
Disease trajectory Name of study; trials
registry #
Lead & collaborating
groups
Clinical question Current status;
Outcome; N= sample
size
Initial surgery EORTC 55971 EORTC, NCIC CTG Primary surgery vs.
neoadjuvant
chemotherapy &
interval cytoreduction
Closed to accrual; no
signicant difference in
OS; N= 718
CHORUS MRC/NCRI Primary surgery vs.
neoadjuvant
chemotherapy &
interval cytoreduction
Open to accrual 2006;
N= 550
AGO-OVAR OP.3
(LION)
AGO-OVAR, AGO-
Austria, KGOG, MITO
Primary surgery +/−
pelvic & para-aortic
lymphadenectomy
Open to accrual 2009;
N=640
Initial chemotherapy
for women with
epithelial ovarian
cancer, tubal
carcinoma, and
primary peritoneal
carcinoma
AGO-OVAR-9 AGO-OVAR, GINECO,
NSGO
Carboplatin/ paclitaxel
+/− gemcitabine
Significant
improvement in PFS;
no significant
difference in OS (10);
N=1567
SCOTROC 4 SGCTG, ANZGOG Flat dosing of
carboplatin vs
intrapatient dose
escalation
No significant
difference (11)
JGOG x JGOG Carboplatin +
paclitaxel weekly vs
every 3 weeks
Significant
improvement in PFS
and OS (14)
JGOG 3019 JGOG Carboplatin (AUC 6) IV
vs IP, both with IV
weekly paclitaxel
Open to accrual 2010;
N= 754
ICON-7 MRC/NCRI, AGO-OVAR,
ANZGOG, EORTC,
GINECO, GEICO, NCIC
CTG, NSGO
Carboplatin/ paclitaxel
+/− bevacizumab (7.5
mg/kg)
Closed to accrual; data
maturing; N=1528
GOG 218 GOG, GOG-Japan, ECOG,
KGOG, NCCTG, NSABP,
SWOG
Carboplatin/ paclitaxel
+/− bevacizumab (15
mg/kg)
Closed to accrual;
significant improval in
PFS; N=1800
MITO-7 MITO, AGO-OVAR,
MaNGO
Weekly vs every 3
week carboplatin/
paclitaxel
Open to accrual 2009;
N=400
GOG 252 GOG Carboplatin/ weekly
paclitaxel/
bevacizumab vs. IP
carboplatin/ weekly
paclitaxel/
bevacizumab vs. IP
cisplatin/ IV & IP
paclitaxel /
bevacizumab
Open to accrual;
N=1250
NCIC CTG OV 21 NCIC CTG, ANZGOG,
GEICO, NCRI, SWOG
Neoadjuvant
chemotherapy->
interval cytoreduction
-> carboplatin /
paclitaxel weeks 1 & 2
vs. IP carboplatin every
/ paclitaxel weeks 1 &
2 vs cisplatin IP/
paclitaxel IV week 1 &
IP week 2/
bevacizumab
Open to accrual 2009;
N=830
AGO-OVAR-12 AGO-OVAR, AGO-
Austria, BGOG, GINECO,
MANGO, MITO, NSGO,
and select US sites
Carboplatin/ paclitaxel
+/− BIBF 1120
(Vargatef)
Open to accrual 2009;
N= 1300
ICON 8 NCRI Carboplatin/paclitaxel
both every 3 weeks vs.
carboplatin every 3
weeks + weekly
paclitaxel vs
carboplatin/ paclitaxel
both weekly
In review; N= 1485
Initial chemotherapy
for clear cell ovarian
cancer
JGOG 3017 JGOG, GINECO, KGOG,
MITO, SGCTG
Carboplatin/paclitaxel
vs. cisplatin/irinotecan
in clear cell cancer
Open to accrual 2007;
N=652
Initial chemotherapy
for mucinous ovarian
cancer
mEOC/GOG 241 NRCI/ SGCTG & GOG,
AGO-OVAR, GINECO,
KGOG, MANGO, NSGO
Carboplatin/paclitaxel
+/− bevacizumab vs
oxaplatin/
capecitabine +/−
bevacizumab in
mucinous cancer
Open to accrual 2010;
N=332
Initial chemotherapy
for primary or
recurrent sex-cord
stromal tumors of the
ovary
GOG 264 (randomized
phase II)
GOG Carboplatin/ paclitaxel
vs. bleomycin/
etoposide/ platinum
for chemotherapy-
naïve primary or
recurrent sex-cord
stromal tumors of the
ovary
Open to accrual; N
dependent on events in
control arm
Consolidation EORTC 55041 EORTC, AGO-Ausria,
ANZGOG, GINECO,
MANGO, MRC/NCRI,
Primary chemotherapy
+/− erlotinib × 2 years
Accrual complete; data
maturing; N=835
GOG 218 GOG, GOG-Japan, ECOG,
KGOG, NCCTG, NSABP,
SWOG
Primary chemotherapy
+/− bevacizumab, both
during chemotherapy
and in consolidation
Accrual complete;
significant
improvement in PFS;
N=1800
AGO-OVAR-16 AGO-OVAR, AGO-
Austria, ANZGOG,
BGOG, GEICO, GINECO,
ICORG, JGOG, KGOG,
MANGO, MITO, NSGO,
SWOG, and select US
sites
Primary chemotherapy
+/− pazopanib × 1 year
Open to accrual 2009;
N= 900
GOG 225 GOG Improved diet &
exercise vs normal
lifestyle in women
disease-free after
primary treatment
Funding pending; N=
1400
Platinum-sensitive
recurrence
AGO-OVAR-OP.2
DESKTOP II
AGO-OVAR, AGO-
Austria, MITO
Evaluation of
predictive factors for
complete surgical
resection
Validation of AGO-
DESKTOP I Score (12);
N= 412
CALYPSO GINECO, AGO-Austria,
AGO- OVAR, ANZGOG,
EORTC, MANGO, MITO,
NCIC CTG, NSGO
Carboplatin/ paclitaxel
+/− pegylated
liposomal doxorubicin
Significant different in
favor of doxorubicin
arm (13); N=976
GOG 213 GOG Carboplatin/ paclitaxel
+/− bevacizumab, +/−
cytoreductive surgery
Open to accrual; N=
660 for bevacizumab
question; N= 360 for
surgical questions
ICON 6 MRC/NCRI, NCIC CTG,
ANZGOG
Carboplatin/paclitaxel
+/− cediranib both with
chemotherapy and in
maintenance
Open to accrual 2007;
stage I, N=50; stage 2,
N=600; stage 3,
N=2000
AGO-OVAR-OP.4
DESKTOP III
AGO-OVAR Cytoreductive surgery
vs no surgery
Open to accrual 2009;
N= 385 (12)
HECTOR NOGGO/ AGO-OVAR,
AGO- Austria, GEICO
Carboplatin/ topotecan
vs carboplatin/
paclitaxel or
carboplatin/
gemcitabine
Closed to accrual;
N=550
MITO-8 MITO, AGO-OVAR,
BGOG, MANGO
Liposomal doxorubicin
vs carboplatin/
paclitaxel, with cross-
over at progression
Open to accrual 2009;
N=253
DDPC-PREOC
(randomized phase II)
SGCTG Liposomal doxorubicin
vs weekly carboplatin/
paclitaxel
In review; N= 130
OVATYON MANGO Lipsomal doxorubicin
+ carboplatin vs
liposomal doxorubicin
+ trabectidin
Open to accrual; N=588
Platinum-resistant/
refractory ovarian
cancer
MITO-11 (randomized
phase II)
MITO Weekly paclitaxel +/−
pazopanib
Open to accrual 2009;
N=72
AURELIA GINECO, AGO-OVAR,
GEICO, MITO, NSGO
Chemotherapy +/−
bevacizumab
Open to accrual 2009;
N=332